Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.

Hyperglycemia, assessed according to HbA1c , and future risk of venous thromboembolism: the Tromsø study.

Recieved:01-Jan-2014 00:00:00

Department of Clinical Medicine, Hematologic Research Group (HERG), University of Tromsø, Tromsø, Norway.
Lerstad, G; Brodin, EE; Enga, KF; Jorde, R; Schirmer, H; Njølstad, I; Svartberg, J; Braekkan, SK; Hansen, JB

HbA1c , a marker of average plasma glucose level during the previous 8-12 weeks, is associated with the future risk of cardiovascular disease and all-cause mortality. To examine the association between hyperglycemia, assessed according to HbA1c , and the future risk of venous thromboembolism (VTE) in a population-based cohort. HbA1c was measured in 16 156 unique subjects (25-87 years) who participated in one or more surveys of the Tromsø study (Tromsø 4, 1994-1995; Tromsø 5, 2001-2002; and Tromsø 6, 2007-2008). All subjects were followed, and incident VTE events were recorded up to 31 December 2010. There were 333 validated first VTE events, of which 137 were unprovoked, during a median follow-up of 7.1 years. HbA1c was not associated with the future risk of VTE in analyses treating HbA1c as a continuous variable, or in categorized analyses. The risk of VTE increased by 5% per one standard deviation (0.7%) increase in HbA1c (multivariable-adjusted hazard ratio [HR] 1.05; 95% confidence interval [CI] 0.97-1.14), and subjects with HbA1c  ≥ 6.5% had a 27% higher risk than those with HbA1c  

Major Topics:
Thromboembolism    hyperglycaemia    Thrombosis    cardiovascular disorder   
Study Group   
Venous Thrombosis    Venous Thromboembolism    cardiovascular diseases    Hyperglycemia    Thrombosis   

Click on any component of the trees below to see articles for any topic that is a member of that branch.